+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical risk factors for poor anatomic response to ranibizumab in neovascular age-related macular degeneration



Clinical risk factors for poor anatomic response to ranibizumab in neovascular age-related macular degeneration



Open Ophthalmology Journal 8: 3-6



To identify OCT-based anatomical features and clinical characteristics for poor central retinal thickness (CRT) response to ranibizumab in neovascular age-related macular degeneration (AMD). Investigating our electronic patient records (Eyeswide), patients with neovascular AMD treated with intravitreal injections of 0.5mg/0.05ml ranibizumab were identified and their notes reviewed. Data collected included gender, age, initial best-corrected visual acuity (BCVA), prior photodynamic therapy, lesion type (classic versus occult), type of macular edema (intraretinal fluid, subretinal fluid, pigment epithelium detachment) and the total number of previous ranibizumab injections. A total of 210 eyes of 182 patients with neovascular AMD were identified. Mean follow-up time was 1.34 years (SD ± 0.77). Central retinal thickness reduction in women was significantly inferior to that in men (p=0.05). Patients with cystoid type macular edema had significantly greater reduction in CRT compared to patients with subretinal fluid (p<0.001) or pigment epithelium detachment (p<0.001). The percentage drop of CRT was no longer statistically significant after the sixth injection. Age, initial BCVA, prior photodynamic therapy and lesion type had no statistically effect on CRT response. Risk factors for poor central retinal thickness response to ranibizumab include female gender and patients with predominant subretinal fluid or pigment epithelium detachment. Furthermore, the anatomical response decreased after the sixth injection of ranibizumab.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052130049

Download citation: RISBibTeXText

PMID: 24949110


Related references

Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration--evaluation in a clinical setting. Bmc Ophthalmology 13: 84, 2013

Factors Associated With Poor Response to Aflibercept After Switching From Ranibizumab or Bevacizumab in Neovascular Age-related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina 47(5): 458-465, 2016

Incidence and risk factors for macular hemorrhage following intravitreal ranibizumab injection for neovascular age-related macular degeneration. Journal of Ocular Pharmacology and Therapeutics 29(6): 556-559, 2013

Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. British Journal of Ophthalmology 98(2): 188-194, 2014

Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration. Retina 34(2): 288-297, 2014

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab. Clinical Ophthalmology 10: 1053-1057, 2016

Retinal pigment epithelium rips after ranibizumab in neovascular age-related macular degeneration: incidence, risk factors and long-term outcome. Klinische Monatsblatter für Augenheilkunde 231(4): 432-435, 2014

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. Clinical Ophthalmology 12: 1877-1885, 2018

Predicting non-response to ranibizumab in patients with neovascular age-related macular degeneration. Ophthalmic Epidemiology 21(6): 347-355, 2014

Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen. British Journal of Ophthalmology 103(7): 900-905, 2019

Genetic Risk Factors Are Not Associated with Wet Age-Related Macular Degeneration Treatment Response to Ranibizumab. Ophthalmologica. Journal International d'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift für Augenheilkunde 239(4): 240, 2018

VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration. Ophthalmic Research 51(1): 1-8, 2014

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration. Clinical Ophthalmology 4: 1271-1275, 2010

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. British Journal of Ophthalmology 94(1): 2-13, 2010

Oct parameters as predictive factors for the visual outcome after ranibizumab therapy in neovascular age related macular degeneration. Archivos de la Sociedad Espanola de Oftalmologia 90(4): 156-163, 2015